Medical Marijuana: A Blessing in Disguise or a Curse for Humanity?

The influx of companies, the launch of pipeline therapies, and the ongoing legalization of marijuana and cannabis are the major drivers reshaping the medical marijuana market today.

Cannabis, popularly known as marijuana, is the most commonly used illicit drug after alcohol, with more than 150 million people using it regularly worldwide. In the United States alone, roughly 11.8 million young adults reported using marijuana in 2017, according to the National Survey on Drug Use and Health. While use among middle and high schoolers has held fairly steady, the 2018 “Monitoring the Future” survey found a rise in daily use among 8th and 10th graders.

Marijuana goes by many names weed, pot, dope, grass all referring to the same plant, Cannabis. It’s smoked, eaten, drunk, and vaped. Smoking produces effects within hours that wear off relatively quickly, while oral ingestion delays the onset of euphoria but extends its duration. Most people use it recreationally but there’s a growing push to harness the same plant for legitimate medical treatment.

Where Does It Come From?

Cannabis belongs to the Cannabaceae family of flowering plants, which spans 170 species across 11 genera. Within the Cannabis genus itself, three species are most widely recognized: Cannabis sativa, Cannabis indica, and Cannabis ruderalis. Despite sharing a common ancestry, each behaves very differently.

Indica strains are prized for pain relief and are the preferred choice for medical applications.
Sativa strains tend to produce a more euphoric high and are favored recreationally.
Ruderalis strains contain low levels of THC and aren’t used recreationally, though their fibrous stems make them useful for textiles.

The Science Behind the Plant

Humans have cultivated cannabis for roughly 5,000 years, yet its underlying chemistry is still being unraveled. The plant contains over 400 chemical compounds, at least 60 of which are cannabinoids including THC, CBD, CBN, CBC, and CBG. Though structurally similar, these compounds behave very differently in the body.

When marijuana is burned, more than 200 compounds are released that act on the brain. THC binds to CB1 and CB2 receptors and, because it’s fat-soluble, crosses the blood-brain barrier easily and lingers in the body for days. THC is responsible for marijuana’s psychoactive “high,” while CBD produces no such effect in fact, it can dampen THC’s impact by acting as an antagonist at the same receptors.

When Marijuana Was Considered a Cure-All

For most of its long history, cannabis wasn’t feared it was celebrated. The earliest documented use of hemp (a low-THC cannabis variety) traces back to China around 1500–1200 B.C., where it was used in medicine, food, rope, paper, and clothing. In India, hemp has been used as a remedy since roughly 1000 B.C.

Cannabis’ medicinal reputation spread over centuries:

1100 A.D. Al-Mayusi documented its use in treating epilepsy.
Middle Ages Avicenna’s influential Canon of Medicine recommended cannabis for headaches, gout, and edema.
1800s Napoleon brought cannabis to Europe after encountering it in Egypt, and Dr. W.B. O’Shaughnessy, a physician in British India, formally introduced its therapeutic use to the Western world.

From the mid-1800s through the 1930s, doctors prescribed cannabis for a wide range of ailments. That changed with the Harrison Narcotics Tax Act, followed by the Marihuana Tax Act of 1937, which made cannabis increasingly impractical to use. By 1970, stricter regulations had transformed what was once a valued crop and remedy into a criminalized substance.

From Remedy to Pariah

Medical marijuana remains one of the most polarizing topics in modern medicine. Is it safe? Ethical to prescribe? Genuinely effective? Legal? Addictive? The uncertainty largely stems from a lack of robust clinical evidence and an incomplete understanding of how the plant’s compounds behave in the body along with lingering fears around dependency and its psychoactive effects.

Legal status varies dramatically around the world:

Fully illegal or heavily restricted: Afghanistan, Algeria, Japan, and dozens of other nations maintain strict prohibitions.
Medically legal: Countries including Australia, Chile, Israel, Italy, Poland, Switzerland, and Thailand permit medical cannabis use.
Fully legal: Uruguay and Canada have legalized marijuana entirely.
United States: 33 states plus Washington, D.C. have approved medical marijuana, though it remains illegal at the federal level.
Europe: Rules vary widely minor possession is tolerated in countries like Spain, Portugal, and Belgium, while nations like Greece, Hungary, and Sweden enforce strict penalties. The Netherlands has effectively decriminalized use.

Where the FDA Stands

The FDA has not approved raw cannabis products for marketing, and cannabis has historically been subject to federal controlled-substance restrictions. However, the FDA has approved certain cannabinoid-based prescription medicines for specific medical conditions.

FDA-Approved Cannabis-Related Medicines

Epidiolex – GW Pharmaceuticals: Approved for seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex.
Marinol – AbbVie: Contains dronabinol and is approved for anorexia associated with weight loss in patients with AIDS and for chemotherapy-induced nausea and vomiting.
Syndros – Insys Therapeutics: Contains dronabinol and is approved for anorexia associated with weight loss in patients with AIDS and chemotherapy-induced nausea and vomiting.
Cesamet – Valeant Pharmaceuticals: Contains nabilone and is indicated for chemotherapy-induced nausea and vomiting in patients who have not responded adequately to conventional antiemetic treatments.

Therapeutics and the Road Ahead

Cannabis is widely explored for chronic pain conditions such as neuropathic pain, fibromyalgia, and rheumatoid arthritis, along with glaucoma, HIV/AIDS symptoms, multiple sclerosis, muscle spasms, and Dravet syndrome. It’s also used to manage nausea and vomiting linked to chemotherapy.

At present, roughly 400 clinical trials worldwide are investigating CBD for conditions ranging from dementia-related agitation and cancer pain to epilepsy, psoriasis, and Tourette syndrome.

Major players in the space include Tilray, Canopy Growth, Aurora Cannabis, Corbus Pharmaceuticals, and Therapix Biosciences, among many others each advancing their own pipeline therapies through clinical trials.

Big pharma is paying attention, too:

Canopy Growth acquired a majority stake in BioSteel Sports Nutrition and completed the purchase of cannabinoid research firm Beckley Canopy Therapeutics.
Aurora Cannabis acquired Reliva, a hemp-derived CBD brand, for roughly $40 million in company shares.
Novartis signed a global supply and distribution deal with Tilray.
AbbVie currently holds the most cannabis-related patents among major pharmaceutical companies, with Merck, Sanofi, BMS, and Pfizer also active in clinical trials.
Johnson & Johnson, through its JLABS Toronto incubator, took on its first medical cannabis company, Avicanna.

What Lies Ahead?

A pivotal moment came when the World Health Organization recommended and the UN Commission on Narcotic Drugs agreed to remove cannabis from Schedule IV of the 1961 Single Convention on Narcotic Drugs, a category reserved for the most dangerous, low-benefit substances like heroin. It’s a symbolic and practical win for the industry, even though individual countries retain the authority to set their own rules.

Still, the UN continues to classify cannabis as a controlled substance, and the WHO has acknowledged real risks: impaired cognitive development, worsened psychomotor performance, and the potential to exacerbate conditions like schizophrenia. At the same time, unlike opioids such as fentanyl, cannabis carries a far lower risk of fatal overdose.

The risks are real and worth weighing:

Regular smoking can injure the trachea and bronchi.
Potential effects include hallucinations, panic, increased stroke risk, impaired lung defenses, and short-term memory issues.
Long-term use may affect brain development, learning, and verbal ability.
The smoke may contain carcinogenic hydrocarbons.
There’s a genuine risk of developing marijuana use disorder.

The Bottom Line

Medical marijuana sits at a genuine crossroads. On one side: a rapidly growing pipeline of therapies, mounting pharmaceutical investment, and easing global regulations. On the other: thin clinical evidence, real health risks, and a regulatory patchwork that varies wildly by country and even by state.

Whether it proves to be a blessing or a curse may depend less on the plant itself and more on how carefully the science, regulation, and industry investment are allowed to catch up with the enthusiasm surrounding it.